Abstract
The treatment of malignant ovarian germ cell tumors is one of the most notable success stories in the annals of gynecologic oncology. It is the constellation of host and tumor factors that combine to contribute to optimal outcomes in the majority of patients: rare tumors that principally occur in girls and young women, predominant unilaterality of the ovarian tumor that allows the potential for fertility-sparing surgery, relatively low frequency of advanced stage disease, excellent chemosensitivity to platinum-based chemotherapy, excellent cure rates, and a relatively small incidence of severe late effects.
This chapter will deal exclusively with the clinical management of malignant ovarian germ cell tumors in adult patients. Whenever appropriate and/or feasible, differences between adult and pediatric practice patterns will be highlighted.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amsalem H, Nadjari M, Prus D et al (2004) Growing teratoma syndrome vs. chemotherapeutic retroconversion. Case report and review of literature. Gynecol Oncol 92:357–360
Beiner ME, Gotlieb WH, Korach Y et al (2004) Cystectomy for immature teratoma of the ovary. Gynecol Oncol 93:381–384
Bhatia S, Abonour R, Porcu P et al (2000) High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346–3351
Billmire D, Vinocur C, Rescorla F et al (2004) Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 39:424–429; discussion 429
Bonazzi C, Peccatori F, Colombo N et al (1994) Pure ovarian immature teratoma, a unique and curable disease: 10 years’ experience of 32 prospectively treated patients. Obstet Gynecol 84:598–604
Brewer M, Gershenson DM, Herzog CE et al (1999) Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 17:2670–2675
Broun ER, Nichols CR, Gize G et al (1997) Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 79:605–610
Bryant CS, Kumar S, Shah JP (2009) Racial disparities in survival among patients with germ cell tumors of the ovary—United States. Gynecol Oncol 114:437–441
Cushing B, Giller R, Ablin A et al (1999) Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the Pediatric Oncology Group and the Children’s Cancer Group. Am J Obstet Gynecol 181:353–358
Dark GG, Bower M, Newlands ES et al (1997) Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 15:620–624
Einhorn LH, Williams SD, Chamness A et al (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340–348
Gershenson DM, Del Junco G, Herson J et al (1983) Sinus tumor of the ovary: the M.D. Anderson experience. Obstet Gynecol 61:194–202
Gershenson DM, Del Junco G, Copeland LJ et al (1984) Mixed germ cell tumors of the ovary. Obstet Gynecol 64:200–206
Gershenson DM, Copeland LJ, Kavanagh JJ et al (1985) Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. Cancer 56:2756–2761
Gershenson DM, del Junco G, Silva EG et al (1986a) Immature teratoma of the ovary. Obstet Gynecol 68:624–629
Gershenson DM, Wharton JT, Kline RC et al (1986b) Chemotherapeutic complete remission in patients with metastatic ovarian dysgerminoma. Potential for cure and preservation of reproductive capacity. Cancer 58:2594–2599
Gershenson DM, Morris M, Cangir A et al (1990) Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 8:715–720
Gershenson D, Miller A, Champion V et al (2007) Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol 25(19):2792–2797
The International Prognostic Factors Study Group (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28:4906–4911
Jimerson GK, Woodruff JD (1977a) Ovarian extraembryonal teratoma: I. Endodermal sinus tumor. Am J Obstet Gynecol 127:73–79
Jimerson GK, Woodruff JD (1977b) Ovarian extraembryonal teratoma: II. Endodermal sinus tumor mixed with other germ cell tumors. Am J Obstet Gynecol 127:302–305
Kattan J, Droz JP, Culine S et al (1993) The growing teratoma syndrome: a woman with nonseminomatous germ cell tumor of the ovary. Gynecol Oncol 49:395–399
Kondagunta GV, Bacik J, Donadio A et al (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23:6549–6555
Kumar S, Shah JP, Bryant CS et al (2008) The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol 110:125–132
Kurman RJ, Norris HJ (1976a) Malignant mixed germ cell tumors of the ovary: a clinical and pathologic analysis of 30 cases. Obstet Gynecol 48:579–589
Kurman RJ, Norris HJ (1976b) Embryonal carcinoma of the ovary: a clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer 38:2420–2433
Kurman RJ, Norris HJ (1976c) Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer 38:2404–2419
Kurman RJ, Norris HJ (1977) Malignant germ cell tumors of the ovary. Hum Pathol 8:551–564
Lai CH, Chang TC, Hsueh S et al (2005) Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 96:784–791
Li J, Yang W, Wu X (2007) Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. Gynecol Oncol 105:769–775
Loehrer PJ Sr, Lauer R, Roth BJ et al (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540–546
Loehrer PJ Sr, Gonin R, Nichols CR et al (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500–2504
Mangili G, Scarfone G, Gadducci A et al (2010) Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol 119:48–52
Mangili G, Sigismondi C, Lorusso D et al (2011) Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. Gynecol Oncol 121:280–284
McCaffrey JA, Mazumdar M, Bajorin DF et al (1997) Ifosfamide and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors; response and survival. J Clin Oncol 15:2559–2563
Messing MJ, Gershenson DM, Morris M et al (1992) Primary treatment failure in patients with malignant ovarian germ cell neoplasms. Int J Gynecol Cancer 2:295–300
Mitchell PL, Al-Nasiri N, A’Hern R et al (1999) Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer 85:2232–2244
Motzer RJ, Mazumdar M, Sheinfeld J et al (2000) Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18:1173–1180
Munkarah A, Gershenson DM, Levenback C et al (1994) Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol 55:217–223
Murugaesu N, Schmid P, Dancey G et al (2006) Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 24:4862–4866
Norris HJ, Zirkin HJ, Benson WL (1976) Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 37:2359–2372
Patterson DM, Murugaesu N, Holden L et al (2008) A review of the close surveillance policy for stage 1 female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer 18(1):43–50
Roth LM, Talerman A (2006) Recent advances in the pathology and classification of ovarian germ cell tumors. Int J Gynecol Pathol 25:305–320
Slayton RE, Park RC, Silverberg SG et al (1985) Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: a Gynecologic Oncology Group study (a final report). Cancer 56:243–248
Tavassoli FA, Deville P (2003) Pathology and genetics of tumours of the breast and female genital organs. International Agency for Research on Cancer, Lyon
Weinberg LE, Lurain JR, Singh DK et al (2011) Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol 121:285–289
Williams SD, Blessing JA, Moore DH et al (1989) Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors: a trial of the Gynecologic Oncology Group. Ann Intern Med 111:22–27
Williams SD, Blessing JA, Hatch KD et al (1991) Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol 9:1950–1955
Williams SD, Blessing JA, DiSaia PJ et al (1994) Second-look laparotomy in ovarian germ cell tumors: the Gynecologic Oncology Group experience. Gynecol Oncol 52:287–291
Williams SD, Kauderer J, Burnett AF et al (2004) Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol 95:496–499
Zagame L, Pautier P, Duvillard P et al (2006) Growing teratoma syndrome after ovarian germ cell tumors. Obstet Gynecol 108:509–514
Zanetta G, Bonazzi C, Cantu MG et al (2001) Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 19:1015–1020
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gershenson, D.M., Brown, J. (2014). Clinical Treatment of Adult Women with Ovarian Germ Cell Tumors. In: Frazier, A., Amatruda, J. (eds) Pediatric Germ Cell Tumors. Pediatric Oncology, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38971-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-38971-9_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-38970-2
Online ISBN: 978-3-642-38971-9
eBook Packages: MedicineMedicine (R0)